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Five years have elapsed since Dm1agk (19) 
announced that he had found that prontosil had an 
elective action against experimental streptococcal infec-
tions in mice and rabbits. At the conclusion of this 
interesting report he says, "Prontosil zeigt eine bisher 
ar.i infizierte Tier nich beabachtete Streptokokkemvirkung. 
Es gelingt, streptokokken infizierte MB.use, die unbe-
handelt innerhalb von 24 Stunden nach der Inferktion 
eingelen, durch subcutane und perorale Prontosilsgaben 
am. Leben zu erhalten. Prontosil zeight eine elektive 
~·virkung bei der Streptokokkensepsis der r..fause". In 
carrying out his experiments he observed that prontosil 
vJas not effective in vitro in preventing the growth or 
killing cultures of streptococci. He di~ not consider 
the drug toxic for he observed no signs of toxicity while 
he was testing the efficacy of the drug in conbatting 
staphylococcal and streptococcal infections in laboratory 
anirn.als. 
His v10rk was confiri.lled durinc: the same year in 
France and later in 1935 Trefouel, Trefouel, Nitti, and 
Bovet (100) found that para-amino-benzene sulfonamide, 
the nucleus of the prontosils,was the active principle 
by demonstrating that it is effective in controlling 
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and curing experimental streptococcal infections in 
animals. 
Interest in these new chemicals became 
actively stimulated on the continent und new cheir.cicals 
with the para-amino-benzene sulfonamide nucleus vrnre 
synthesized. Lore experimental vrnrk on experimentally 
infected animals was carried on, and the clinical use 
of the drug increased. 
The medical professions both in .America and 
England were apparently unaware of the fact that an 
important group of 6.rugs had been found to have extra-
ordinary power in curing both experin:ental and clinical 
streptococcal infections. This is explained by the 
fact that people naturHlly pay more attention to the 
journals written in their own tonfue. In addition to 
this, the drugs were difficult to obtain in large 
enough quantities to carry on any sicnificant work 
because .American manufacturers had not yet perfected 
suitable methods of synthesis to make available cheap 
supplies of these drugs to investigators. 
This unawareness, however, came to an end 
after Colebrook and Kenny (13) and Buttle, et al, (11) 
of Zngland,and Long and Bliss (60) made their renorts 
concerning the effects of this group of drugs in 1936. 
Since that time, the para-amino-benzene sulfonarrlide 
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(sulfanilamide) group of C.rugs has been very widely used 
for treatine: both clinical and experimental infections. 
Clinically and experir~entally tlley have been ehJ)loyed 
for practically every known infection. It is no wonder 
that the statement is so often made that patients are 
first treated vJi th sulfanilamicle and if' this has no 
effect upon the course of the illness a history of t~e 
illness is obtained and a physical examiEation of the 
patient is r1ade to discover the nature of the patient's 
coEplaint. \Ji th such widespread use, both the beneficial 
and deleterious effects of these substances could be 
observed repeatedly. 
These drugs have, without doubt, brought about 
a wonderful advance in the treatment of bacterial infec-
tions. In the case of' such substances, it is relatively 
easy to become too enthusiastic over their effect and 
ascribe to them the properties of a cure-all. That 
these substances have been found to have toxic effects 
was not unanticipated since their nucleus is the benzene 
ring with an arnino-group attached. Such drugs have long 
been known to be responsible for toxic effects upon ·the 
blood picture and hematopoietic tissue. 
In conparing the incidence of serious toxic 
effects of the drug upon patients to those cases in 
which no serious toxic changes occur, it is apparent 
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that the percentage is small. Due to the fact that the 
drugs do have toxic effects should discourage their 
promiscuous use in conditions where there is no real 
indication for their use. Their use, however, should 
not be neglected in those cases in which it has been 
proved th&t they are curative and beneficial, e.g., 
streptococcal, meningococcal, gonococcal, and pneurno-
coccal infections. 
One of the nost interesting toxic effects is 
the change which occurs in the blood picture of both 
animals and patients given these Grugs. Our interest 
has been stimulated to some extent by the results 
obtained in a few aninal experirr_ients at the University 
of Nebraska (64) and also by the interesting reports 
of blood dyscrasias which have been incJ:·easeing ever 
since the reports by Young (108) and Jennings c:.nd 
Southwell-Sander (46) have been published. In this 
thesis a brief review is being made of agranulocytosis 
and hemolytic anemia associated with the administration 
of the drugs of the para-amino-benzene sulf onanide 
group. 
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1.1hen Plw-_rier ( 77) reported in A1Jril, 1937, a 
death due to leucopenia follovJine; treritrn.ent of subacute 
bacterial endocar ii tis by sulfanilamide, the experimental 
production of blood changes produced by giving the 
drug to experimental animals had not yet been accomplished. 
Hawking (36) was unable to produce blood changes. 
M1,rshall, et al, ( 69) published their work concerning 
the toxicity of sulfanilamide in January 1938. They 
had fed 0. 2 grarns of sulfanilamide per kilogram to two 
dogs for two months and had not found any change in 
either the red cell, white blood cell, or in differen-
tial blood cell counts. Large doses of sulfanilamide 
were given to two dogs and four rabbits to determine 
whether sulfanilamide affected the blood count v1hen 
given in larse doses in a few days time. These doses 
ranged from 3.5 to 6 grams of the drug per kilogram 
in 2 to 5 days tiroe. No effect upon the blood picture 
was observed. Hagercan (33) gave 20 grams of sulfanila-
mide to a group of mice in 14 days time. Since he found 
that the spleens of these mice had much hemosiderin 
deposit and tJ:at the eosinophils of the bone marrow 
had increased, he suggested that the drug was able to 
destroy red blood cells and cause an allergic response 
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of the bone marrow. Finkelstone and Sayliss (26) 
noticed abnormal erythrocytes and nucleated red blood 
cells in the blood of rabbi ts to which he fed 1. 2 graL'.S 
each day. 
Domagk ( 19) vvas unable to produce any changes 
in the blood of experimental anir<ials with prontosil and 
neo-prontosil. In 1937 he (20) found that sulfanilyl 
Eulfanilamide and various derivations of that drug were 
able to cause various changes both in the white and 
blood cell picture. These changes were inconsistent as 
far as the white cells were concerned. The mono-methyl 
derivative of sulfanilyl sulfanilamide caused the red 
blood cell count to drop when given to laboratory animals. 
Bone marrow studies were not made to determine the 
reaction of the bone marrow to the drug. 
Kreutzman and CaTr (57) gave 8 rabbits doses 
of )rontosil for a period of 21 days. The dosage was 
slightly higher than the recornnended. dose. The peri-
pheral blood counts did not consistently change through-
out the exi)eriment but the red blood cell counts 
incceased from 10 to 157b after the drug had been dis-
continued. Spleens were moderately congested and the 
single lobe eosinophils of the bone marrow were increased. 
These findings were interpreted to be suggestive of a 
mild bone marrow derre::sion caused by the continued 
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administration of prontosil. 
Vlhen '!Jhi tby ( 103) introduced sulf'apyridine 
he thought that it ·would produce fewer toxic effects 
than sulfanilamide. V!ien (104) gave 0.25 mgs. per cram 
of sulfapyridine to four rats for 14 days and 0.5 rags. 
per gram to another group of four rats for 2 weeks. He 
used the same size dose of sulfanilamide for tv10 other 
groups of rabbi ts for the sarie length of time. Two 
blood count'.::3 were made each week and no changes were 
found in the peripheral blood picture. Ho changes in 
the blooc'1. pictures were found in cats given 1 gram of 
sulfapyridine in ? days or in dogs given an identical 
dose. When he fed larger doses of sulfanilamide and 
sulfapyridine, 1.5 to 3 mgs. per gram, to rats for 
15 days, he found that those animals receiving sulfa-
nilarnide became anenic, had an inc,~·eased amount of 
urinary porphyrin output, but those that had received 
sulfapyridine did not develop such chances. 
During 1932> some of the effects of both small 
doses of sulfanilamide given over a period of five 
weeks and large doses given to rabbits were observed at 
the Nebraska University College of ~·.=edicine ( 64) 
15 rabbi ts were given 4 grar1s of sulfanilamide per kilo-
gram in a 24 hour period. At the end of the sixth day 
after the initial dose 13 rabbits were dead. The two 
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remaini~g rabbits were killed. The red and white blood 
cell counts showed no consistent chance. The 
differential counts shifted to the left anc' the reticu-
locyte counts increased. Counts and studies made of the 
bone marro~ stained by the panoptic stein revealed no 
significant alterations. Bone marrow counts of 8 normal 
rabbits were made in order to have a basis of comnarison 
f o:!'.' the bone marrow counts nade on the marrow from the 
experimental animals. In studyin~ the chronic effects 
of sul:t'anilar:1icle VJe made observations on tvvo groups of 
rabbits. One group of four received daily doses of 
sulfanilamide, 1.0 grmn. per 9 kilograns oi' vveight, for 
a ueriod of 35 days. The other group, consisting of 
five rabbits, received the same dose, but each rabbit 
had a five-hour fever treatment each ·week throughout 
the course of the experiment. Studies of the peri-
pheral blood throur;hout the experiment Viere made at 
weekly intervals and it was found that the small daily 
doses of the drug had no consistent effect upon the 
blood picture. Of the group of four, one animal died 
of pneu.monia. The same dosage of sulfanilamide com-
bined with fever did, however, result in blood changes 
in 3 rabbits. One rabbit was killed accidentally 
uuring the second week but no blood changes had 
developed at that time. Of this group the one rabbit 
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that was li vine~ at the close of five VJeeks had had no 
blood cell changes. The other 3 rabbits died 10, 15, 
and 24 days L<fter the beginning of the experiment. 
Two of these rabbi ts had a leucopenia at the tilne of 
death with decrease in all the cellular elements. The 
other rabbit also had a leucopenia but the great 
reduction in the total count was due to the fact that 
only 2% of the cells were granulocytes. Unfortunately 
our bone marrow preparations were unsatisfactory. 
Duri~g 1939, several interesting reports 
concerning the effects of drugs of the paro.-anino-benzene 
sulfonamide group were nade. Rosenthal (86) and 
Nelson (73) studied the effects and histopathological 
changes in hens and rabbits following administration 
of sulfanilamide and sul:ranylil sulfanilaaide to 
rabbits and chickens. They found that these drugs both 
have cumulative toxic effects for both rabbits and hens. 
Bone 1,mrrow from 11 rabbi ts t1-,at had received repeated 
doses of sulfanilamide were examined. Of 11 preparations 
.studied, 3 were ncrriaJ_, ~ s..LigJ:'.'"Gly hypoplastic 'lnd 5 were 
moderately hyperplastic. In 3 o~ .tne ~yperplastic bone 
marrov1s the proportion of early forms ot cej_ls to lute 
foriw vms norr,1al. vne .tiyperplastic tissue was i·ounct 'GO 
contain increased mnnbers 01' stem cells and early granu-
locytic :t'orn1s and the fifth of this group of hyperplastic 
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marrov:s showed that an increase in the nature for1:1s 
of cranu..Loc~;0es na6. occurred. It '.vas i'ounc. tb;.t one 
of the typoplastic tissues had a reduction in Ghe 
:1W:1ber of nor:rnoblasts. The bo:rn ::ia.rrm: o:t' rabbi ts 
tre&ted ~ith aisulfanilamide had less pronounced changes 
occur after the ~rug had been adn1nisterec in repeated 
c.ose s. Of 9 bone ras.rrows studied, 6 'JJere normal. Of 
the three vvhich ·were abnormal, one liad. a hypopJ.asia 01· 
granulocytes, one a hypopl&sia ol' normoblasts, and 
one bone 2~·,arrov1 prep:c:ration hacJ. a hyperplasia oi' ir.1L~ature 
granulocytes. All the bone ;;1arTm·1 stuciie s ~;::-.~Ge on · Gllu 
hen bone narrow given ei the11 su..Lranilaraide or di su.L1'a-
nilamide in repeated doses showed hynoplasia. 
Later ir: 1939 Rosenthal and 3auer ( 87) were 
able to G.enonst:.:·::•:G.:: r·.yc.roxylamine deri v2,ti ves in the 
urine 01' Tatb, raobi ts, dogs, and ;~an afte1· they llaa l1ad 
sulfanilar:1icle '.-~drn.iniste1~ed to the~:1. This 'i!E1S founG. in 
lc.r(~:er CJ.u2ntj_ties in the u.rine of' r:1an ,_;rw :rab~:.;i t th::en 
in -cne utlwr aninm.Ls. These oxicl.a ti on ·Jro0.ucts '.vere 
1·ounu to be of greater toxicity than the orif;illa.L c.I'ug 
adninistrated. 
Eolitor anG Hobin::::on ( 7;:;) in 19o'd rmblished 
the results o:':' tl:cir s-cuay u1 cute, cur:mlative and 
chronic toxicity us -.iell ;;~s phar::,"acolot_:ical effects of 
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sul:t'anilar!1ide C:Lnr.:'.. benzyl ;::;ul:f anilmnic~e upon l<J80 ani1a1-s. 
~oe~s to 111~"ich tLey ave sul1'uni1-a:no_e for 3 week neriods 
had no blood picture chn~eas. In every case the~ observed 
th2.t s ul:f'anilm::ide \"J2.S ver·y rmch rn.ore toxic tho.n benzyl 
sulfanilamide. They had no deaths of animals fed as 
nuch as 45 ,zraus per kiloe;rau for 10 c:ays. }!:_, tholosical 
chs.nc;es they found in the tissue~~ o:i' anirials ·.vhich are 
3ii?1lif icunt i.vere Lirge, hyperemic, pigrn.ented S})leens. 
The pier:1ent YJas both ii1 on Clnd non-iron conto.ir'..ing 
substances. The bone na:r·ro·,·,; Yi'..S noder:.1tely hyperplastic. 
l)igrr1ent was also present in the lymph glands and in the 
convoluted tubules of t~e kidneys. These findings indi-
cated that a testruction of blood ele~ents occurred 
1.·1hich w·~~s :responsible for inc1·cased stin:ulc:.tion of 
bone rnarrov1. 
That sulf~'pyricii:ne is L':cr~.1 less _nli. non-toxic 
tor nice - ,'~:.s concluded by Johannsen ( ,±:7) uurinc >is 
investiz. tion of the toxic 2nl therapeutic effects of 
the druc. This is not the sar:e couclusion ':ihich 
I'.oli tor and Robin~ on as ·well as Antopol 'J.nd Hob ins on ( :3) 
reached during their experinents '.Vi th sulfap:,Tidine •,Ji th 
various kinds of labor2tory animals. Bone marrm1 hyper-
plasia of the rn.yeloc;enous ele:::ients as ·well as lyrn.pl10id 
hy1Jer:)lasia and nigmentation of the S}Jleen w0.s found. 
Peripheral blood studies 0ere not nade in these 
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experiments. 
Very interestinc is the ~ork reported by 
Eiggins c_:ulC1 IIachelle.. ( 37) r:L'hey i11duced anemia in rats 
in a period of 10 days to two weeks by using doses of 
1 grarn. of sulfanilamide to 1 kilogran of' vJeicht. They 
attributed the anemia due to a direct effect the sul-
fanila:-,1ide has upon the blood cells o1' the rat. They 
found coproporphyrin in the urine of rats and say that 
its presence i:1clicates a bone ~:-iilrrov1 derangenent. 'v'fhen 
they gave rats the same dose of sulfanilar:lide in connec-
tion v1ith five 50 mg. doses of nicotinic acid, anemia 
developed as it had when the drug was afuninistered 
without the nicotinic acid. Bone narrow studies were 
made. No impaired hemopoiesis was founcl. There was 
some erythroid shift but the essential structure of 
the bone marrow was not ir::paired. 
1-Iachella and Higgins (65) have been able to 
induce anemia in rats by afu1inistering doses of varying 
quantity to different groups. Their work is especially 
interesting since very similar cases have jeen reported 
as a result of the therapeutic use of the drug in treat-
ing infections in man. The· experiment and its results 
are described briefly. They used four different doses 
qf sulfanilanlide on each of four differe~1t groups of 
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rabbits. ?or co~venience, 1 list of the doshge ~nd 
groups is included. 
Dosage 11:0. of Hats in Grou2 
0.25 gms. per Kg. 6 rats 
0.5 gms. per 1Cg~. 6 rats 
1.0 gms. per iCg. 12 rats 
2.0 gms. per IC@;. 12 rats 
They were able to induce anemia in these rats in v1hich 
the degree and rapidity of onset were dependent upon the 
size of the dose given. ~ list of the results they 
obtained is included. 
1. Increased color index. 
2. Anisocytosis and macrocytosis. 
3. Rapid c.:.ecrease in red blood cell count and hemo-
globin. Degree and rapidity of drop dependent on the 
size of the dose. 
4. Rats were thirsty, cyanotic, drowsy and 
irritable during the onset and throughout the 
course of the (~_rug adriinisti'ation after chane:es 
had begun. 
5. Initial drop in white blood cells was 
followed by leukocytosis. 
6. Steady and progressive drop in the total 
hemoglobin also was observed. 
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7. In the bone marrow, the erythroid and mye-
loid cells were increased. A transient increase 
in eosinophilic r1etarnyelocytes vms also noted. 
8. Examination of tissues was made • Findings 
were hemorrhagic gastritis, black spleens enlarged 
lymph elands, and dark livers. These animals had 
a gradual recovery fro1n the anemia after the c~rug 
was discontinued. 
In summarizing the vvork of the effects of 
various sulfonamide drugs upon the blood cells and 
henopoietic systems it is concluded that these drugs 
do affect the blood cells and the hemapoietic tissues. 
The presence of increr.tsed amounts of pi0 11ent in the 
spleen and in soLe cases in other tissues of the body 
indicates thCct an incre,c~sed amount of red blood cell 
destruction occurs when these Ci.rues are adninistered. 
That the red cell count and hemoglobin does actually 
decrease was indicated by t~ohella's and Higrins' (37)(65) 
work. There is little work showing changes in the 
peripheral white blood cell counts since most of the 
work of investigation of the harmful effects of these 
drugs on experimental animals did not include blood 
counts. Since the bone -,--[arrow did have an altered pic-
ture in most instances, it is rec:tsonable to conclude 
that had the peripheral blood picture been studied, the 
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changes found during histopathological studies of the 
bone marrow would have been reflected by the peripheral 
blood. 
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AGRAlWLOCYTOSIS AND H.~rrnLYTIC ANEl<IA: 
SENSITIVITY REliCTIONS OF TB:;_q; BOlTE: Y.~ARROVI. 
Introduction 
Since 193? the number of reported cases of 
hemolytic anemia and agranulocytosis associated with 
or following therapy with sulfanilamide and allied 
compounds has inc:ceased. That this should occur is 
natural since the total number of patients t:;:eated con-
stantly increases and provides opportunity for more 
blood disturbances to develop. Undoubtedly the few 
observations of blood changes associated with these 
drugs in animal vvork is due to the fact that the course 
of the e:~fect of the drug has not been so closely 
vmtched as in human beings treated with the substances, 
nor have as many aninals been exposed to the drugs as 
human beings. 
Hemolytic Anemia 
Before cons iderj.ng the red blood qell and 
white blood cell disturbances fo:;_lowing the use of the 
sulfonamide drugs, a brief review of the nature or 
character of the conditions known as hemolytic anemia 
and agranulocytosis is given. 
Hemolytic anemia is a condition characterized by 
hyperbilirubinemia, urobilinuria, hemosiderosis, 
- l? -
reticulocytosis anQ normoblastic hyperplasia of the bone 
marrow, and a high grade of leu.kocytosis if large 
numbers of red blood cells are suddenly destroyed. 
It may be due to peripheral hemolysis caused 
by a direct hemolytic effect of certain chemicals, 
bacterial toxins, and drugs or due to an idiosyncratic 
effect caused by complex antigen-antebody reactions of 
foreign proteins or various chenical compounds.(2?) 
Examples of direct hemolytic poisons are phenylhydrazine 
trinitrotoluene, hydrogen arsenide, n-propyl disulfide, 
snake venoms, saponins, and bacterial toxins. Fitzhugh 
(27) says that the hemolytic effect of dinitrophenol, 
acetanelid, :~nd antipyrine is due to an individual 
idiosyncrasy of an occasional person, for these sub-
stances do not cause a hemolytic anemia in the larger 
percentage of people to whom the drug has been given. 
Since the advent of sulfanilamide, both Long (60)(61) 
(62)(63) and Fitzhugh (2?) think that the hemolytic 
anemia which develops during sulfanilaraide therapy is 
a manifestation of an anaphylactic or idiosyncratic 
effect which the drug has on an occasional patient. 
It is ad..111itted that hemolytic anemia is due 
to complex sensitivity reactions but the factors which 
are concerned in the actual production of an occasional 
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sensitivity are not known. This is true not only for 
this type of allerf'Y but for all allergic phenomena. 
Factors to be considered are heredity, hormonal mechan-
isms, dysfunction of liver and spleen, fatigue states, 
traum1tic shock, toxemias which include putrefactive 
distul.'bances and various bacterial and protozoan infec-
tions, deficiency states. Radiation effects, also 
are to be considered. Fitzhugh (27), Jackson and 
Parker ( 43) , I\:racke and Parker ( 55), l·ladison and 
Squier (66), Pepper (76), and Rosenthal (84) all feel 
that these factors are to be considered as etiological 
agents in the production of various sensitivity reactions 
of the blood and bone marrow • 
.Agranulocytosis 
Introduction. In 1922 Schultz (90) reported 
a condition which he named agranulocytosis. The disease 
he described was characterized by an acutG onset, Vlith 
chills, fever, jaundice, ulcerative and gangrenous 
lesions in the mouth, and leucopenia with granulocytopenia. 
All of the six cases 'Which he reported occurr2d in 
middle-aged women vlho had been in good heal th. The 
six cases were all fatal. According to most workers who 
have investigated and observed agranulocytosis since 
that time, this is reg~rded as a new disease. (27)(22) 
(23) (45) (55) (66) Pepper(76), however, thinlcs that the 
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condi tioc:., :i:'on1.erly known u:,; putrid so:'e throat, was 
an analagous concl.i tion. The other workel'S feel that 
since blooC counts have teen done for over 50 years, 
certainly the disease would have been reported before 
1922 had it actually existed. 
Definition. Before the discussion of 
agranulocytosis or agranulocytic ane,ina is continued, 
the condition should be defined. At first in glancing 
through the literature one is confused by the large 
number of different terms used to nane the syrn_ptom 
co11plex. The expressions acute granulocytic angina, 
agranulocytosis, malignant granulopenia, and acute 
primary granulocytopenia are synonomous terms accord-
ing to Jackson and Tighe.(44) Kracke (53) says that 
the term agranulocytosis, strictly speaking, is a 
misnomer for it means an increased number of i~'Jl::ature 
granular cells. Fitzhugh (27) suggests the term per-
nicious granulocytopenia. · JTor the purpose of avoiding 
confusion in this discussion, the term agranulocytosis 
is being used, and the condition is defined as an acute 
disease characterized b:, extreme leukopenia and granu-
lopenia and systemic reactions which in turn may be 
followed eit~er by no infection, localized infection, 
or Generalized infection. 
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~tiology. The exact etiology is unknown. 
There are, however, predisposinc etiological factors. 
Pepper (76) has observed th~t there is a hicher incidence 
of this disease among allergic patients than in non-
allergic people. }(racke ( 54) is well known for his 
work both in the clinical investigation of the disease 
as v1ell as the ex~)erinental production of the concl.ition 
by various substances such as benzene, hydroquinone, 
and ortho-oxybenzoic acid. Ee says it is a disease of 
the rn.yeloblastic tissues followed b':r a loss of resis-
tance, resulting in overwhelminp; infection, but the 
exact etiological agent is not known. L.adison and 
Squier (66) were able to cause a fatal agranulocytosis 
in 1 of a group of 11 rabbits, by benzene drugs and feel 
that these d.rur::s are in some rmnne1, responsible for a 
sensitization of the bone marrow v1hich results in 
sudden leucocyte decrease. That drugs are responsible 
for the condition, especially those of the benzamine 
group, is the ri1ost tempting of theories, but at tim.es 
cases of agranulocytosis develop when there is no 
history of the use of drugs of this group. Kracke (55) 
quotes the work of Plum who made a very extensive 
survey of the incictence of agranulocytosis in Denrnark. 
He was able to correlote the incidence of ~granulocytosis 
with the incidence of use of ai>ninop~.'rine. The greatest 
- 2l . 
incidence of the dise8Se occurred durine 1933 and 1934 
when the largest a111ount of the (:_rug vms being- co;·:_sumed 
in Demnark. This was Vl8ll denonstrated by a e;raph he 
constructed in i:1hich it '.':as de1::onstrat0d that the curve 
representing the use of anino:pyrine and that representing 
the incidence of agranulocytosis were parallel. 
Another interesting fact regarding the inci-
dence and distribution of agranulocytosis is that 90% 
of the cases occur in the United States and G-ernany. 
( 44) ( 53) ( 55) ( '76) This corresponds to the area in 
which aminopyrine was most freq_uently used a fevJ years 
ago. By the tir1e sulfanilamide became a po:pulor thera-
peutic drug, the incidence of agranulocytosis had 
decreased greatly associated 'Jith the lessened use of 
aminopyrine. It is as yet too early to measure the 
effects that the introduction of this new product will 
have upon the total incidence but, judging by the 
increasing number of reports of agranulocytosis 
associated vJi th therapy with this group of drugs, it is 
very likely that the incidence has made a very definite 
increase. 
The horrn.onal factor as an etiological factor 
in the production of agranulocytosis is suspected to 
play a role because the condition occurs most often 
between the ages of 30 and 40. The ratio of the 
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incidence occm'ri:1.g in wouen and men is 3 to 1, the 
greatest percentage being found in women. 
That the standard of living has an effect 
is well borne out by the fe,ct that before sulfanilam.ide 
was introduced, the occurrence of agranulocytosis was 
most corm1on in that class of people of higher econoI.'1ic 
standards.(55) Of this group nurses, physicians, and 
me:nbers of the family of physicians were :rounci to have 
the dise&se most freq_uently. 
-v'lhen Schultz (90) described agranulocytosis 
he said that the cause vms due to an acquired sensitivity 
of the leukocytes, endothelium, and leukopoietic tissues 
to certain drugs or other allergens. Despite much obser-
vation and investigation since that tiiie, little more 
can be said in regard to the disease today. If it is 
a bone marrow idiosyncrasr does it result in a lack of 
a rimturation factor or a lacl;: of a chemotactic factor 
which interferes with the delivery of the blood cells 
into the vascular system? F'itzhugh (27) calls the con-
dition pernicious granulocytopenia for he believes 
that the condition is caused by an arrest in the 
riaturation of e·ranulocytes ·which is analagous to the 
arrest of maturation of erythrocytes in pernicious 
anemia. He believes this to be true because he has been 
unable to find a decrease in the myeloid cells of' the 
- 23 -
bone marruw, but !:us found a hT_t!erIJlasia of the early 
for~s of granulocytes. Furtherruore, the lesion of the 
leukopoietic tissues is reversible to a certain point 
if it Las not cc,,ntinued so long that apla.sia finally 
results. Reraissions of the disease are ch2racterized 
by an outpouring of young cells before the nature forr11s 
appear. Fitzhugh has said thbt possibly the sudden on-
set is due to the fact that the inciting factor may 
cause the cells to stick to the endothelial lining and 
·thereby cause a sudden marked drop in the cell count. 
That no evid.ence of abnormal distribution of granulocytes 
is found during histopathological studies is explained 
by the fact that the adherent cells disintegrate 
r·apidly. 
Overwhelming septic conditions do occasionally. 
result in a profound' as well as fatal leukopenia asso-
ciated with a profound reduction of the granulocytic 
cells. It is the opinion of Kracke (53)(54), Pepper (76) 
Jackson (43) (44), ~ 1Iadison and Squier (66), and Fitz-
hugh (27) that the sepsis which is often associated with 
agranulocytosis is not the actual cause but rather the 
result of agranulocytosis which depletes the resistence 
of the tissues to infection by the lack of defensive 
agents. Domagk (21), however, does not believe that 
true agranulocytosis develops as a result of the 
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adrdnistration of the amino-benzene sulfonamide com-
pounds but thut the granulocytopenia is the result of 
the effect of the etiolo~ical agent producing the disease 
for which the cirug is being used. That a granulocytopenia 
can develop in response to a severe infection is true. 
Schilling (89) says that this is either brought about 
by the overwhelming irritation of a severe acute sepsis 
or persistent drain of a long continued inf'ection. In 
the case of sulfanilamide, however, it is hardly 
possible to believe that the infections have been so 
much more severe during the past few years that the 
infection i tsel1' and not the sulfonamide drugs have 
been responsible for the inc eased number of reports 
of agranulocytosis. In this connection the case 
reported by Ives (42) is very interesting. A negro 
patient after nine days of illness with hemolytic 
streptococcic angina had a total white blood cell count 
of 9000 vJi th a coraplete absence of granulocytes. The 
patient had a gr<-'<yish black necrotic uer:tbrane over his 
pharynx, he vvas confused, drowsy, and cor;.;.plained of a 
headache and joint pain. The lowest vvhite count was 
1200, with no granulocytes one day after hospital 
admission. 5 cc. of prontosil every four hours and 
60 grains of sulfanilamide as well as intramuscular 
liver extract an~ intravenous pentnucleotide were 
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administered as soon as the blood findings -were made. 
Recovery began on the second day '~.fter beginning of 
therapy and the patient had an uneventful course of 
illness in the hospital. In this case the sepsis was 
overwhelming enough to cause a severe granulocytopenia, 
and the drug was indicated because the toxic, septic 
process had to be controlled. 
Pathology. The pathological changes of 
agranulocytosis are located chiefly in the bone narrow. 
If angina occurs, necrosis and ulceration without 
evidence of 8ranulocytic invasicn occur in the mucous 
menbranes, chiefly those of the tongue, nasopharynx, 
and 9harynx. Necrotic lesions are occasionally found 
in the vagina, gastro-intestinal tract, and bladder. 
The bone marrow changes are the most 
ir:iportant pathological findirn s of this disease. 
Kracke ( 53), Jackson ( 44) ( 43), Fitzhugh and Krur1bhaar 
(28), and Darling, et al., (22) find that there is a 
rn.uturation arrest Vii th nyperplasia at the sten cell 
stage of the myeloid elements of the bone marrow if 
the disease is rapidly fatal. If the disease is pro-
longed there is an inc1:'eased number of plasna cells and 
lyrnphocytes with hypo1)lasia of the myeloid cells. 
There is, however, no evidence of degenerative changes 
occurring in the bone n"arrow cells. If the bone marrow 
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is degenerated it is either the result of an infection 
or poor fixation of the tiDsue. Bone marrow 1'rom 
patients who are recoverinB froG the infection has 
increased nur,1bers of raore nature cells. Rosenthal (:35) 
finch; tli::;t tha bone ma=-rovJ is aplastic. Pepper ( 76) 
also believes that an aplastic as ··,ell as a degener2ted 
bone w-1.rrm.1 if; found in these conditions. It is possible, 
as Jackson (44) says, to misinterpret bone marrow find-
ings, especially if the tissues have been i:nproperly 
fixed. It is also possible th~t Pepper (76) and Rosen-
thal (85) both examLled bone marrov1 frm1 patients '1vith 
a prolonged course of the disease. Jackson (44) also 
thinl;:s that the original report of the bone L1arrov1 find-
ings by Schultz ( 90) ar·e also frequently wisinterpreted 
to rr1ean aplasia of the bone rnarro·i.1 instead of a matura-
tion arrest. To us it seems that the conclusion may be 
reached after having examined the reports oi' the vc:irious 
authorities that the bone marrow may be either aplastic, 
hyperplastic, or hypoplastic. 
Course of Disease. Clinically, the course of 
the disease has an acute onset. Often there is a prodomal 
period of malaise. The fever is high, ranging from 104° 
to 1070 F. The patient is prostrateo., usually con~lains 
of severe headache, has chills and a sore throat. 
Often there are ulcerative lesions both in the nose, mouth 
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and throat which have a peculiar gray green appearance 
with ve:_'y little or no inflammatory change. The breath 
is foul. .1:;.long v1i th these finc:iings ancl symptoms there 
is extreme leuko:penia v.Jith a great reduction in granu-
locytes. Often no granulocytes are found in the 
peripheral blood ancl the total count may be as low as 
only a few hundred cells. A few reports told of 
counts less than 100 white blood cells per cubic 1nilli-
meter. Often positive cultures are obtained from the 
blood, but the bacteria are not recarded as the 
etiological agents of agranulocytosis, but the result 
of invasion of the body tissue2 as a result of the 
absence of the defense barrier ~hich the cranulocytes 
provide in protecting the body against bacterial infec-
t ion. The disease has a rapid course and may terminate 
fatally in frori 2 to 6 days or recovery when it occurs 
is complete in 2 weeks. Jackson ( 44) reports a 78fo 
mortality. Kracke (53) found that 85~; of 250 patients 
affliced with agranulocytosis died. Liadi;rnn and 
Squier (66) observed 14 cases following aminopyrine 
injection. Of this group 8 died. It is uncertain what 
the exact mortality rate is, but there is no doubt that 
it is high. 
Diagnosis. Diagnosis is based upon the 
followine; findL1gs: Hemorrhage doec' not occur, few 
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irm_ature white blood cells are present in the blood at 
the heicht of the disease, neither the livernor the 
srJleen are enlarged, and l·yrr1phadenopathy does not occur 
except that ex})lained by local areas of sepsis. In 
addition to these findines recovery, if it occurs, is 
CO!tplete in two ·weeks, relapses are uncorDraon. Usually 
careful questioning and investieation ·will elicit the 
fact that soEe form of a benzene or aminobenzene drug 
has been used. Bc:,ne marrow chant::es may be an aid to 
diagnosis, but if we go on the assumption that it may 
be aplastic, hyperplastic or hypoplastic, it is necessary 
to correlate all the finGings to arrive at a definite 
diag·nosis. 
Differential diacno:ds may be very difficult. 
( 44) ( 45) Ott.er conditions from which it IilUSt be 
differentiated ar0 overv1helmin2; infections; benz ol, 
gold, bismuth and arsenic poisoning; acute leuh:emia; 
aplastic anemia; and acute infections such as typhus, 
raeasles, r:mmps, influenza, malaria, dencue fever and 
roseola which characteristically ~lave lovJ total v1hi te 
counts. Careful blood studies, thoroue;h exar~ination, 
and caw:ete histories are all valuable aids in estab-
lishinc a diagnosis. An aplastic bone r:iarrov1 with blood 
findings inci.icatillC a severe anenia, thror:lbopenia, and 
neutronenia is typical of aplastic ane~ia. If thare is 
- 29 -
a hi;; tcry oi.' ucir1ini ~0.tra ti 011 of col cl, ::.rsenic, bisr:mth, 
or tenzol before the o~set of such f indin~s the 
etiolozy of tha aplastic anenia is ostablished. 
Acute infections ( 53) seldon cause i~~uch 
diagnostic difficulty becau~1e of cheracteristic sic:;ns 
and sy1npto.i,1s which do not harmonize '.Ji th the blood 
~yscrasias. Both acute leukemia as well as a neutro-
penia due to an overv1hGlr:dnr sa1;s is may be very cliff i-
cult to dif:_'erentiate froe B.{~;ranulocytosis. The 
neutropenia associate~ ~ith sepsis is termed acranulo-
seps is by Kracke. ( 5~)) This condition rnay follov1 surrdcal 
procedures (81)(102) aB well as acut3 infections (42) (9) 
and it I:1ay be very difficult to cleternine '::hether the 
s:rr1:9tons and firnli1ic:s are pathognononic of an idio~Jathic 
agrarrulocytosis or of an exhaustion or intoxication caused 
o:/ the s e·otic process. A bone :1aITO' .. ' strnly may give the 
only clue by degenerative and toxic chances found ~ithin 
the cells. Severe septic processes of this type are apt 
to have an associ.=i.ted seco:J.dary a;:ienia \'Jl1ich may also be 
helpful in er:Jtablishing the truo dia[·T1osis. 
Jackson (45) warns of the ease in which acute 
leukemia and agranulocytosis 1~iay be cor~fused. Only 
careful study of the patient's hematological picture 
correlated '.:i th the physical findings will, in so:ie cases 
result in a definite diagnosis of either one of these 
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EE:.:OLYTIC J\IC1 :IA ASSOCIA'l1:S:D ·. IITE SULFONILAI.IIDE 
Al'TD RELATED COI:FOUIWS 
Introduction 
Both mild, slowly progressive he:nolytic anemia 
and acute heraolytic anemia vvith a sudden clrop in hemo-
globin and r·_ d cells aI·e afrnociat·ed ':tith the acLministra-
tion of sulfanilamide and sulfapyridine. 
Progressive Hemolytic Anemia 
Lone (63)(59)(61) and ~ood (106) as well as 
Garvin (30) have all observed that a progressive hemo-
lytic anemia with a fall of from 10~& to 20% hemoglobin 
occurs in sone p:::tients. Jennings s.nd Southwell-Sanders 
(46) made the first report of a slowly progressing 
hemolytic anemia associated with sulfanilamide ad.min-
istration. This is most often noticed in those patients 
who have received the drug for several weeks and most 
often appears after the tenth day. The reticulocyte 
count increases and there may or may not be a slight 
urobilinuria. All of these three workers make their 
statements after having observed many patients, but they 
do not state the percentage of patients treated over a 
long period of tirne that developed the low grade, 
chronic hemolytic anemia 
Incidence. Bigler, Clifton, and ~:rerner (7) 
- 32 -
studied the bloocl picture of 33 patients v1hile recei v-
ing sulfanilarnide. They observed no severe 2nenia, nor 
did they find that any of their patients developed a 
low grade aner1ia. In fact, they say that often the 
hemoglobin of their patients apparently increased. Counts 
were done two times each week during a period of 28 
days on 50 ambulatory patients beinB treated by sulfa-
nilarnide by Britton and Cowkins.(10) The dosage 
prescribed was 0.5 gram three tines a day for 14 days. 
During that time they detected no evidence of a hemo-
globin or red cell decrease. Hageman (32)(34) in 
reviewing 114 cases treated with sulfanilamide found one 
case of hemolytic anemia. Carn.pbell ( 12) observed the 
blood picture of 10 cases being treated with sulfa-
nilamide. Anemia was not found but the reticulocyte 
count increased. It is possible that destruction of the 
red blood cells did occur, but it was so slight that 
anemia was not detectable because the bone marrow was 
able to replace red cells as fast as they were destroyed. 
Long, Bliss, and Feinstone (63) have observed 
that chronic anemia may also result when sulfapyridine 
is used. Hodes, et al., (39) studied 71 cases of 
pneumococcic pneumonia treated with sulfapyridine and 
found no significant hemoglobin change. Barnett, et al., 
(5) report no anemia from sulfapyridine therapy in a 
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group of 23 cases. No anemia is reported by Evans, 
et al., (25) who used sulfapyridine to treat pnemnonia. 
Rosenthal and Vogel (84) who use the sane d.rug have 
found that henolytic anemia does occur. 
Discussion. This type of anemia is not 
regarded as a grave conplication of sulfanilamide 
therapy. Long and Bliss (59)(61)(62)(63) do not regard 
this complication of severe enough consequence to dis-
continue the .. ~rug unless the hemoglobin has dropped below 
60?~. The bloou regenerates quickly if the drug is 
stopped and if the infection is not yet controlled and 
the hemoglobin has dropped to the 60~b level they advise 
continuation of the c~rug v1i th a blood transfusion. 
Acute Hemolytic Anemia 
The acute hemolytic anemia which develops is 
both spectacular and serious. Harvey and Janeway (38) 
made the first report of this toxic effect of sulfa-
nilamide. The early s~.~mptoms, before the anemia 
develops, are nausea; dizziness; increased urobilin; 
fever; and symptoms of tox~city.(106)(30)(61) Other 
findings reported by these workers, as well as those 
whose cases are tabulated in Table I, are a rapid, and 
pronounced fall in the hemoglobin antl the number of 
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TABLE I 
Tabulation of Cases of Hemol 
Drugs of the Para-Amino-Benze 
Total Total 
Drug Days Diagn 
8 gma. 
Prontosil 3 Pneun 
90 gms. 36 
Sulfan. Hours Tonsi 
24 gms. Mastc 
Sulfan. 4 Masto:l 
9 gms. 
Sulfapy. 3 
Lil!-· 66 gms. StrE 
Sulfan. 6 Pneur 
* Bone marrow was very hyperplastic w: 
proliferation. 
TABLE I (Con 
Tabulation of Cases of Hemol: 
Drugs of the Para-Amino-Benze1 
Sex Total Total 
Reference Age Drug Days Diagn< 
Male 21 gms. 
Wood(l06) 36 Sulfan. 5 Tonsi: 
Same Pt. 7.8 gms. 
1 Yr. later Sulfan. 3 Tonsi 
Rosenblum Male 2 gms. Tonsi 
Rosenblum Sulfan. 2 Ot. M, 
Nelson 
Scott- Female 48 gms. 23 
Young 32 Sulfan. Days Goner 
Harvey Male 22.8 gms. Strep 




















TABLE I (Con 1 t) 
Tabulation of Cases of Hemolytic Anemia Due to 
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two million in 24 hours. L:arked reticulocytosis, leu-
kocytosis, bilirubinemia, urobilinuria, porphyrinuria, 
jaundice, and occasionally jaundice are also associated 
with this condition. 
In considering predisposing f~ctors, it was 
found that no one type of infection was associated with 
the acute anemia. The size ol' the dose and the concen-
tration of the Qrug in the blood do not seem to be 
factors for both high and low values were associated 
with the syndrome. The carbon dioxide corribining power 
in 19 of ~ood's (106) 21 cases of acute hemolytic anemia 
cases was within normal limits. Table II is a table 
taken from a report by Wood (106) aemonstrating a 
hypersensitivity of the red blood cell system to sulf'a-
nilamide after the four patients had recovered from a 
previous attack of acute hemolytic anemia. Case A.D. 
is a case cited b~ ~illis.(105) 
patients had fever. 
All of' the 
Incidence. Acute hemolytic anemia is not more 
prevalent in one sex than in the other. It is, however, 
more prevalent in chilclren than adults. 'Nood ( 106) has 
observed 522 patients treated VJith sulfaniJ.amide. Of 
this group 144 were children and 378 were adults. A 
total of 21 cases of acute hemolytic anemia occurred in 
the children's group and 9 in the adult group, or 8. 377; 











No.4 7 Mos. 
Female 
No.5 9 Mos. 
TABLE 
Table from Wood (106) Summarizing Five 
Anemia Took Place Followin_g_a Second c, 
First Course of Trea tme: 
.. ,--...... .... -..-,---~-·------
Days of Total Dr 
Diagnosis Treatment Dose % 
Acute 
Tonsj_lli tis 5 21.9 
Ophthal. 
Neo. 111. 7 .~. 
Pulmon. 
Tb. 7 11.1 .• 0 
Otitis 
Media 3 4.5 
Pyelitis 3 5.8 
treated with sulfapyridine has as yet been reported. 
Hemolytic anemia, however, also occurs in patients 
treated with sulfapyridine.(29)(84) No hemolytic 
anemia associQted with either prontosil or disulfanila-
mide has been reported but 2 cases treated with 
diamino diphenyl sulfone are reported.(62) 
Course and Prognosis. The onset of the 
disease is fror. 24 to 72 hours after the beginning of 
the drug administration. The maximum anemia occurs 
from the third to seventh day, most often on the fifth 
day. 
The m.ortality rate is low because the condition 
responds well to withdrawal of the drug and blood 
transfusions. Two fatal cases are reported, one by 
Wood (107) and the other by Koletsky.(52) (See Table I.) 
The case reported by Koletsky died 6 days after the be-
ginning of the first dose of sulfanilamide and 2 days 
after the drug was discontinued. No transfusions were 
available. The death following the development of 
anemia reported by Wood (107) is evidently due to the 
fact that transfusions were started too late in the 
course of the disease. The drug had been discontinued 
on the sixth day but no transfusion was given w1til the 
twelfth day. The patient died on the sixteenth day 
after the drug had first been started. 
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Possible Li.echanism. That the acute hemolytic 
anemia, v1hich develops during the course of therapy with 
several drugs of the sulfonamide group, is due to an 
individual idiosyncrasy is very evident. That the con-
dition does not occur in every case is one proof of this 
and the fact that 3 out of 4 patients have a recurrence 
of the s:yraptoms when the drug is repeated is evidence 
that these patients are hypersensitive to the drug.(63) 
As with all idiosyncrasies, the mechanisli. by ·which it 
works is not understood. There is no bone marrow 
depression as is indicated both ~y the reticulocytosis 
and leukocytosis as well as by bone marrm·; studies that 
reveal a hyperplasia of' both erythroid and nyeloid ele-
ments. The drug does not hemlyze the red blood cells of 
these patients, nor are the cells of these patients more 
easily her10lyzed by hypotonic saline than in normal 
patients. (53)(106)(107) Histopathological study of 
other tissues, besides the bone !arrow, reveals changes 
typical of any severe hemolytic anemia. The most typical 
finding is hemosiderin deposits in the tissue. So the 
pathology gives no clue to the mechanism of the anemia 
production. Both Long (63) and Wood (106) report.the 
presence of porpllyrin in the urine. Ri.:n.ington ( 82) 
has found that porphyrin increases when sulfanilamide is 
eiven to patients. he believes that the porphyrin 
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production is not related to the bilirubinernia associated 
with red cell destruction, but he thinks it is produced 
because the sulfanilamide r.iay possibly be responsible 
f'or a disturbance in pigment metabolism with a deep-
seated effect upon the hemapoietic system. Ee says that 
hemoglobin forns bilirubin without passing through a 
porphyrin stage. It is necessary to conclude that the 
mechanism of the production of hemolytic anemia by 
drugs of this group is not understood. 
Treatment. Treatnent of hemolytic anemia is 
simple. Two main conditions must be fulfilled. In the 
first place, the drut; responsible for the. idiosyncrasy 
must be eliminated. This is accomplished by forcing 
fluids and discontinuing the drug. These drugs are 
excreted almost entirely by the kidney (68)(75) so 
water diuresis is very necessary. In the second place 
blood transfusions are necessary not only to tide the 
person over the critical period until the bone r.iarrow is 
able to regenerate blood cells to replace those des-
troyed but also to prevent irreparable tissu~ damage in 
case of profound anemia. I.iany of these patients becorae 
so anemic that cyanosis is not present even though a 
considerable portion of the remaining hemoglobin has been 
changed to methemoglobin.(78) Furthermore, it is possible 
for toxic effects to manifest theEJ.selves from 3 to 4 days 
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after the last dose(l8), and it seems too great a risk 
to take a chance and hope that the hemoglobin and red 
cel~will not drop farther even though the drug has 
been discontinued. That these methods are satisfactory 
in preventing mortality is indicated by reports.of 
Long (63), '/food (106) {93) (38) ('74). Occasionally (63) 
if the infection is very severe and there is no control 
of it yet established when the anemia occurs, it is 
justifiable to continue the drug therapy provided the 
patient is carefully watched and repeated daily trans-
fusions are given to control the anemia. 
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LEUKOP?.:NIL N,.'U AGRr.I'TITLOCYTOSIS A.GSOCI.Ar:L1ZJ ·.'ITE 
SULFAlTILAl.'.IDE AI''.D H3L1~TED COEPOlJl:rns. 
Introduction 
The literature concerning disturbances of the 
white blood cells due to the benzene-sulfonamide drugs 
is very much greEJ.ter in amount than that relating of 
red blood cell disorders. Undoubtedly this is due to 
the fact that agranulocytosis is a very severe and often 
fatal complication following not only the para-amino-
benzene sulfonamide group but also the benzene drugs, 
es1-:iecially the benzamines, to which the group under 
discussion belongs.(56) 
Agranulocytosis is, however, not the only 
disturbance of white blood cells encountered when the 
effects of these drugs on the leukocytes are reviewed 
Other conditions are leukopenia and hyperleukocytosis. 
Leukopenia 
Trunper in 1937 (77) in a letter addressed to 
the lfow England Journal of l'Iedicine saicc that two 
cases which he had been treating ~ith prontosil and 
prontolyn had had nmrked reductions in the total white 
count. One patient with a septic mastoid had dropped 
from 18, 800 white blood cells to 4, 000 with 357~ granu-
locytes. The white count in the other patient suffering 
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from puerperal sensis dropped from 20,000 white blood 
cells to 5,000 with 50%-60% granulocytes. This seems 
to be the first report which appeared in the literature 
vvhich indicated that sulf'anilamide and prontosil may 
affect the blood picture in some manner. In both 
instances the white cell count rose when the drug was 
discontinued. 
Some believe that the derivatives of sulfa-
nilw1ide as well as that drug itself have a depressive 
ef~ect upon the white blood cells. This is the opinion 
of Bigler (7) who studied the leukocyte response of 33 
patients to sulfanilamide therapy. Since they observed 
the nu..111ber of leukocytes became less during the course 
of treat:nent, they concluded that the cell drop was an 
effect upon the cells and not a natural result of the 
termination or recovery from the original infection. 
That tlJ_ey made that conclusion seems especially strant;e 
when it is fOWld during examination of their reports that 
no one type of cell v1as decreased out of proportion to 
the other cells. Although they did find that in three 
instances the total count was slightly below 5000, no 
evidence of granulocytopenia is present. 
Britton (10) observed a group of 50 ambulatory 
patients who received the drug for two weeks, but whose 
blood counts v;ere done 2 times a week, both during the 
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treatment and the followine two weeks. Of this group 
32 had no marked variations in white cell counts. In 
14 cases the count dropped to bet~een 5000 and 4000 
and 4 cases had white cell counts th8t dropped below 
3000. At the beginning none of the patients had either 
a leukocytosis or leukopenia. Blood counts were done 
on 17 untreated normal controls during the same period. 
The types of cases being treated consisted of cervical 
eriosions, urinary infections, gonorrhea, and one c&se 
of syphilis. Of their 14 cases whose count fell to be-
tween 5000 and 4000, 2 cases were lowest during the 
first week, 3 cases lowest during the second week, and 
9 cases were lowest during the third week, that is, 
the first week after the medication had been discontinued. 
Those 4 cases in ·which the white cell counts dropped 
below 4000, had that occur during the third week. In 
only five of their cases was a true neutropenia 
observed "nhere the granulocyte count dropped below 2000. 
After analyzing their findings, they found tlIBt there 
vms a tendency for the average total white cell count 
to drop during the first wetk and remain low for the 
following two weeks with a rise to norEal occurring at 
the end of the third week. 
TiNo hundred and. fifty cases treated with 
sulfapyridine were summarized by Lloyd, et al. (58). 
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They say that a small proportion of these patients had 
slight but definite decrease of the leukocyte count 
associr1ted with a neutropenia nnci relative lyrnphocytosis. 
They observed no dangerous depression of the rranulocytes 
and say that the v1hite count quickly rose to normal levels 
vd th discontinuation of the c~rug. 
Hodes, et al., (39) treated 71 cases of 
pneumonia with sulfapyridine. He reports 5 cases of 
mild granulocytopenia and one case of severe granulocyto-
penia v1hich all recovered c::_s soon as the drug was dis-
continued. Flippin (29) reports one ca.:;e of leukopenia 
in a group of 100 cases treated with sulfanilamide. 
From the reports of the results of sulfapyridine 
therapy it is apparent that a depression of leukocytes 
is a~1sociated vvi th the administration of this drug. 
That the drug is an etiological factor concerned in the 
cell depression is evident since the count returns to 
normal after it has been discontinued. Whether these 
decreases in the total v;t~ite count are in the nature of 
a mild hypersensitivity reaction or due to a direct 
toxic effect upon the white blood cells or marrow, we 
have no way of knowing. That either one of the two 
conditions may exist is possible. In every case the 
condition was mild anc5 no other toxic symptoras were 
associated with the change in the blood picture. 
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In the 408 cases observed bv Long (62)(63), 
no mild or transient Cdses of leukopenia associated 
with •ranulocytopenia are noted. The only white blood 
cell disturbances encountered was one case of agranu-
locytosis which developed during treatment at the 
hospital and one case of agranulocytosis which developed 
in an out-patient. Patients in their care who had 
leukopenia as a result of an infection recovered f'ron 
this sy.mpton as soon as the infection ·was brought under 
control either by sulfanilamide, sulfapyridine, or some 
related drug. Long and Dliss, therefore, conclude that 
these drugs have no ;.1irect effect upon the white blood 
cells except th<-1t occasionally agranulocytosis may 
occur associated with the a&ninistration of these Li.rugs. 
Reference to a case cited by Ives (42) has 
been made earlier in which agranulocytosis associated 
vii th a heri1olytic streptococcic angina improved after 
sulfanilrunide was given. Long (63) also has said 
that sulfanilamide is indicated in those cases of leu- . 
kopenia and agranulocytosis associated with an infection, 
for the removal of the infection will remove the 
etiological f· 0 ct or. It seems, hmJever, that this 
opinion should be slightly modified. Strasser and 
Singer ( 96) say that if any disease which is characte:r:ized 
by leukopenia is treated by sulfanilamide or its 
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derivatives the depression of the white blood cells is 
apt to inJrease to an even still greater degree. 
He cites a case of miliary tuberculosis treated with 
prontosil in which agranulocytosis developed. This was 
t eated with nucleotide and the white count rose. This 
argues for the curnulative effect of the drug. Later a 
3 day course of treatment vJi th the same drug re~rnl ted in 
total disappearance of granulocytes from the blood. The 
count rose after' the drug had been discontinued and a 
transfusion had been given. 
Agranulocytosis 
The first cases of agranulocytosis associated 
·with sulfanilamide and prontosil afu:iinistration were 
reported by Pluc'-er (101); _Borst (8,); and Young (108) in 
1937. Each of these cases terminated fatally. After 
these accidents had occurred, more rsports were made of 
both severe granulocytopenia and agranulocytosis result-
ing when this group of drugs were given. 
Etiology. Long (62) thinks that the agranulo-
cytosis which occurs and is associated with therapy by 
sulfanilai11ide or other members of the group is different 
from the type of reaction seen in the cases of agranulo-
cytosis or profound granulocytopenia associated with 
aminopyrine. He bases this opinion on the fact that often 
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patients who have recoverec_ fro~: the dise~~se do not 
subsequently develop granulocytopenia or other synptoms 
when test doses are given, or therapy is reinstituted 
for other inf'ections. Schwentker (92) also has observed 
a lack of hypersensitivity to these drugs when they are 
adninistrated. 
Jennings and Southwell (84) believe the condi-
tion of ai:::;ranulocytosis follov1ing sulfanilamide adminis-
tration is similar to the cor::.di tion ·which occasionally 
occurs follov1inr:~ the administration of benz ol, tolu ol, 
anO. their rutro and. anide product2. 'rhey reminL. us of 
the fact that sulfanilanide and its rel:,_ted substances 
are me~1bers of this group of drue;s. 1"/i th amido-pyrine, 
how ver, it is not known hov.7 i;iuch of the c~ruc is a:pt to 
cause an attack. 'Ji th sulfanilamic1e, hoi:1ever, it has 
often been observed thc~t ufter 20 gra1:.1s t'.ave been admin-
istered in a period usually over 14 days the bloo 1J 
disturbances of the ~hite cells are apt to occur. The 
fact th3.t da!!l2.f:e to the ~;hi te cells does not occur 
m1til after a le.r.~;e amount of the drug 11:::.s been given 
for a lon{:· tLr_e causes Shecket e.nd Price (93), Taub and 
Lefkowitz (99) to think that it is the cw,iulative e1'fect 
of the drus given over a lori:; period of tine that fiEally 
wears out the myeloid tissue of the bone marrow. Since 
large doses do not affect all natients in the same 
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manner it v1oulcl Sl3e1~1 that or:.ly th0 ore;anically G.eficient 
marrows are affected. 
Allen and Short ( 1) , ==cGuire and : ~cGuire ( 70) , 
and Jones and I~ller (49) have been ablo to renort 
sens i ti vi ty to the drug by patients a:.Cter they had 
recovered frod agrunulocytosis after a course of sulfa-
nila::iide treat.!.'lent o.nd therefo:r:·e recard it as a :reaction 
of the he:v1apoietic system of a hypersensitive nature. 
Again we mention another f~ctor previously 
cited (96), tll3.t one should })roceed cautiously v1ith the 
use oi' pro~1tosil if there is already evidence of some 
'Vhi te blood cell dyscrasia. One ca::e of' ae:~ranulocytosis 
which developed in a patient that had railiary tuberculosis 
was cited. Coxon and Forbes ( 15) reported a case of 
typhoid which developed an acranuloc~tosiE after the 
patient had been treated with sulfapyridine. Four cases 
of whoopi:ig couc;h v1i th bronchopneunonia, which were 
treated v;i th s ulfapyridine and also developed ac;ranulo-
cytopenia are reported by Dolgopol.(24) All the 
diseases, tuberculosis, whooping cough and typhoid, are 
characterized by neutropenia and vJe v:or::.der if the 
agranulocytosis v1hich occurred nay not have been influ-
enced by the fact the.t chai1;·0~ s already vJere present 
in the bone marrow before. the clruc therapy began. 













Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Total Total Onset of Lowest 
Diagnosis Age Drug Days Diagnosis W.B.C. Treatment Outcome 
Pye lo- Female 64 gms. 960 
cystitis 61 Pront. 39 38 Days 1% Gran. None Died 
Barthol in Female 18 gms. 2400 
Abscess 18 Sulfan. 19 19 Days 0 Gran. None Recovery 
Rheumatic Female 12 gms. 3200 Liver E.xt. 
Fever 11 Sulfan. 7 0 Gran. Transf. Recovery 
Died. Hem. 
Pneumoc. Female 80.9 gms. 75 Liver Ext. after drain. 
Peritonitis 10 Sulfapy. 26 3 Days Later 0 Gran. 'I'rans. neck abscess 
Male 38.0 gms. 1600 
Gonorrhea 22 Sulfan. 27 27 Days 1% Gran. Died 
TABLE III 
Tabulation of Reported Cases of 
GranulocrtoEenia and Agranulocrtosis 
Sex Total Total Onset of Lowest 
Reference Diagnosis Age Drug Dara Diagnosis W .B .C. Treatment Outcome 
Transf. 
33.62 gms. Liver Ext. 
Female Pront. & 400 Nucleotide 
Bresgen Pyelitis 55 Sulfan. 21 21 Days 0 Gran. X-Ray Died 
800 Transfs. 
Corr 1st Presc. Female 35 gms. 8~ Neutro. Pentnucle-
Root by Osteopa. 22 Sulfan. 15 2% Eosin. otide Died 
Nucleinic 
Coxon Female 54 gms. 100 Acid 
Forbes Typhoid . 42 Sulf apy 17 0 Gran. Calcium Recovery 
Transfa. 
Culbreath Puerp.Sep. Female 21.7 gms. 17 Days 700 Pentnucle-
Ellenton Malaria 40 Sulfan. 7 After last dose 0 Gran. otide Died 
Transfs. 
Cutler Female 1050 Pentnucle-
Crane Salpingitis 11~ Days 0 Gran. otide Recovery 
TABLE III 
Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Total Total Onset of Lowest 






















































































Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Total Total Onset of Lowest 
Reference Dia~osis Age. Drug Da1s Diagnosis W .B.C. Treatment Outcome 
Transf. 
G.C. Female 49.2 gms. 3 Days 1350 Liver Ext. 
Hoffman Arthritis 19 Sulfan. 18 .After last dose 0 Gran • Fe.Sulf. Recovery 
Septic 4000 Withdrawal 
Trumper Mastoid - - - - - - - 35y& Gran. of Drug Recovery 
Male 
24 gip.s. 
Streptoc. Drug discontinued because a drop occurred in the number 
Hohmann Gonorrhea -- 7.2gms.Pront. 12 of granulocytes on the 12th day. Decrease did not con-
tinue after drug discontinued. 
Septic sore Agranulocy. Recovery 
throat with Ma.le Before Drug 1200 Liver Ext. Soon as Drug 
Ives Agranulocy. 52 - - - Given 0 Granu. Pentnucle. Began 
61.3 gms. Transfs. 
Puerperal Female Pront. & 1520 Pentnucle. 
Johnston Sepsis 23 Sulfan. 20 20 Days 0 Gran. 10 Tab.allowed Recovery 
TABLE III 
Tabulation of Reported Cases of 
GranulocztoEenia and Agranulocztosis 
Sex 'l'otal Total Onset of Lowest 
Reference Diat:5!!osis Ag_e Drug Dazs Diagnosis W .B .C. Treatment Outcome 
68.45 grns. Transfs. 
Puerperal Female Pront. & 3500 Pentnucle. 
Johnston Sepsis 33 Sulfa.n. 22 22 Days 0 Gran. 5 Tab.All~wed Recovery 
over 
Jones Male 30 gms. 2300 Yellow bone 
Miller Gonorrhea 26 20 20 Days 5% Gran. Marrow cone. Recovery 
Transfs. 
Female 16.25 gms. 1000 Pentnucle. 
Marcus Pyelitis 35 Sulfan. 25 25 Days 0 Gran. Bone Marrow Recovery 
450 
X-Ray.Intra- Recovery. 
McGuire Rheumatoid Female 27 gms. Muse.Blood. Sympt.Recur 
McGuire Arthritis 35 Sulfa.n. 30 30 Days 0 Gran. Pentnucle. with Drug 
Rheum.Fever Ma.le 54 gms. 300 Transfs. 
Model Endoca.r. 20 Sulfan. 18 18 Days 0 Gran. Pentnucle. Died 
TABLE III 
Tabulation of Reported Cases of 
GranulocxtoEenia and Agranulocitosis 
Sex Total Total Onset of Lowest 
Reference DiaB,!!osis Age Drug Dais Diagnosis W.B.C. Treatment Outcome 
Female 36 gms. 6 Days 600 Tranfs.from 
Pearson Sinusitis 60 Pront. 24 After Last 2% Gran. Leukemia Died 
Album. Dose Patient 
Subacute 3 Days 
Bacterial Female 43.25 gms. After Last 400 
Plumer Endocarditis 54 Sulfan. 23 Dose 0 Gran. None Recovered 
Subacute Male 282.6 gms. 200 
Sailor Bact.Endocar. 39 Sulfan. 23 23 Days 0 Gran. None Died 
Schwartz Pentnucle. 
Garvin Chancroidal Male 56 Gms. 300 Liver Ext. 
Koletsky Ulcer 32 Sulfan. 21 18 Days 0 Gran. Transf. Died 
Schwartz Pentnucle. 
Garvin Gonorrheal Male 66 gms. 1350 Liver Ext. 
Koletsky Arthritis 57 Sulfan. 13 13 Days 20% Gran. Transfs. Died 
TABLE III 
Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Tota.I Total Onset of Lowest 
Reference Diagnosis Age Drug Days Diagnosis W.B.C. Treatment Outcome 
Schwartz 15 gms. 2000 Pentnucle. 
Garvin Fem.ale Sulfan. 3 3 Days 25% Gran. Liver Ext. Recovery 
Koletsky Erysipelas 22 
Schwartz Pentnucle. 
Garvin Puerperal Female 100 gms. 400 Liver Ext. 
Koletsky Endometri t:ts 26 Sulfan. 17 19 Days 0 Gran. Trans:fs. Recovery 
Shecket Male 64 gms. 50 Pentnucle. 
Price Pneumonia 45 Sulfan. 15 15 Days 0 Gran. Trans.fa. Died 
Bronchopne.u. 
Strep.Sore Male 52.39 gms. 3 Days 1200 
Shull en berger Throat 44 Sulfpy:. 21 After la.st dose 0 Gran. Pentnucle. Recovery 
Liver Ext. 
52 gms. 3 Days 1500 Pentnucle. 
Sutherland Spesis 37 Sulfapy. 12 Arter last Cbse 0 Gran. Transfs. Recovery 
TABLE III 
Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Total Total Onset of Lowest 









































































Tabulation of Reported Cases of 
Granulocytopenia and Agranulocytosis 
Sex Total Total Onset of 
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of this condition. This is suc·~est3d since in the 
4o ca:: es li;:Jtsd in Table III, 26 are fe:ualss and 15 
D.re mu.les. Two cas·::;s are not li~Jted .·,::ts to sex. 
Possible etiological factors considered ~hich 
may play a part in the develOJ)ment of' the:=; af;ranulocyto-
penia are bone marrov; da"«1age "by previous infection, bone 
t1arrow chc::.nP:ed by cumulative affect of long continued 
drug therapy, sex, abnormality of bone ::iarrovv of' 
obscure oriein, idiosyncrasy to drugs. That various 
factors may be concerned is evident, but the Iilechanism 
of the production of this abnor:~iali ty reJ'iains unknown 
as in the case of other druB idiosyncrasy. A typical 
geographical distribution is not apparent in the 
case of t:'lis d.::.'uc idiosyncrasy because the -'-rug is so 
universally used ·.inC! not conf'i:ied so closely to Germany, 
United States, and Denmark as was the case with 
a.rninopyrine. Ca . es are also reported fron }'ranee ( 79) 
and fro5 other c~untries. The class distribution also 
does not hold for the sulfanilamide croup because it 
is used for treating the infections of every class of 
peo:i;:ile. 
Pathology. The pathology of' the bone inarrow 
is reported in Table IV • .As in aGranulocytosis associated 















Decrease in myeloid cells. 
Increase in lynphocytes. 
Slight decrease in the nucleated cellu-
lar elements. Llost cells ic;:::ature. 
Proninence of reticule-endothelial cells. 
Ifony lymphocytes and megakaryocytes. 
Many mononuclear cells. J\Yo segmented 
cells. Imrnature and developing 
erythrocytes. 
Hyperplastic and aplastic changes. 
Aplastic changes 'nere most marked. Ho 
areas of erythrocyte cle;:,truction. 
:\Iyeloblastic arrest. 
Few mature neutrophils and erythrocytes. 
Maturation arrest with stem cell hyper-
plasia. Reduction of nucleated red 
cells accounted for the secondary 
anemia. 
Hyperplasia 01· ster11 cells. Absence of 
rnatu:Le cells oi· nyeloiu series. 
A decrease in the total cell count -,·iith 
a maturation arrest. 
Bone raarrov1 aplasia. 
Course of Diseqse. See Table III for infor-
nation concerning reports of ce.ses 01' sevGre ,c~r::inulocyto-
penia and agranulocytosis. Th8 ono sy-;.-;~pto;:i e:~nd f'incJ_ing 
associated nost often with this condition is feve~, \Jhich 
is an important warning signal of so r~:::my of the severe 
toxic effect,.:; or the sulfanilamide crouv of drugs. Fever 
usually precedes skin eruptions, toxic hepatitis, as 
well as acranulocytosis. Other warni signals which 2ay 
or may not be an sie;n of beginning of this severe distur-
bance is a fever \1hich continues even thoue:h the symptoms 
and sie,ns of the original infection have disappeared, 
eruptions, c;radual but slow decrease in the hemoglobin, 
and any abrupt rise or fall in the white blood count. 
Table III is a tabulated record of available 
case reports in the literature. Fron a study of the 
cases we fin~ that in addition to the fever associated 
with both the onset and the course of' the disease there 
are chills, malaise, abdominal pains, sore throat, extrema 
toxicity, weakness, headache, confusion, and a foul 
breath. 'J;1here is always leukopenia with pro:f'ound e;ranu-
locytopenia which nay result in conTJlete disappearance 
of all granulocytes. There nay or nay not be angina. 
The reports of cases cited from the table 
indicate that the v'li tharawal of the urur, does not always 
halt the progressive drop in white blood cells inITTediately 
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but the counts often continue to drop 2 or 3 days after 
the last dose. The count may not :irop UYJ.til a few days 
after ths last dose is given. Often a ste:~dy but slow 
decrease in the total white count vJi th no disturbance of 
ratio of different cells is a sign of the beginnine of 
the dyscrasia. 'l\venty-six cases occurred in females, 
15 in males. In two instances the sex is not stated. 
There is no predominence of any age group. Ho single 
type of infection predominates. The total nose of the 
drug ranges from 14.5 to 100 grarns in a period of 7 to 
39 days. 'Jith two exceptions the onset ranges fron1 14 
to 21 days after the beginning of the <lrug's administra-
tion. Sulfanilamide, sulfapyricline, and. pro:atosil had 
been used in various instances. Of the 43 reported cases, 
le were fatal. 
Treatr;ient. Treatnent of '.Jhi te blood cell 
dyscrasias associated with d.rugs of the sulfanila:r:i.ide 
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froup is both prophylactic Gnd active. 
The best vmy to avoid the development of 
agranulocytosis associated -c'.'i tL the para-amino-benzene 
sulf'onamide drue:;s woulcl be not to give the drug. 
Since that is impossible because thec~e drugs are valu-
able aids in saving live~ it is necessary that the 
drug should not be given unless there exists an indica-
tion for its use. Vll1en it is used, the course of' the 
patient's illness should be carefully watched. Fever, 
rash, slowly progressing aneraia, slow response to 
treatment, gradual decreasing Vlhite blood count with or 
without neutropenia should all be regarded as warning 
signals. Other VJarning signals are development of 
jaundice, and any abrupt rise or fall in white blood 
cells. 
Shecket and Price (93) say that if the efficacy 
of one of these drugs in conbatting the infection is 
not demonstrated from four to seven days after the 
beginning of the administration, the drug should not be 
continued, for they relieve the prolonged administration 
and the consequent large amounts of drug result in a 
cumulative toxic effect. Along this sa1:1e line of thought 
is Bresgen's (9) advice to give large doses of the drug 
for a short time and therebye avoid the long continued 
effect of the drug upon the myeloid elements. He also 
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says that too small inadequate doses do not stop the 
infection but keep up a chronic low grade type of 
infection which results in added strain upon the bone 
marrow along with the effect of the drug. Shecket and 
Price (93) also remind us that the fact that the drug 
has been discontinued does not absolve us from co!1tinu-
ing to watch the patient carefully, for often the 
agranulocytosis does not shov1 itself until several 
days after the last dose of the drug. (96) 
If there is already depressed or a changed 
bone n;arrow due to the nature of· an infectious disease 
or other toxic factors, the question of' w'ether or not 
to administe1· sulfanilamide should be carefully con-
sidered. 
Carr and Hoot ( 14) advise that the J)hysician 
and nursing staff be very watchful as long as the 
patient is on the drug, but especiA.lly so after 14 days 
have elapsed and the patient continues to receive it. 
'.'ihenever a white count has been reduced to 3000 or 
4000 the drug should be O.iscontinued irnnediately and the 
patient carefully vmtched. (84) Hohmann (41) advises 
cessation of the drug tt~ereapy whenever the granulocytes 
are decreased even thoueh the total white count has not 
decreased. 
After having considered the various suggestions 
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made which are all valuable in the prevention of serious 
blooG dyscrasias, it is evident that it is very foolish 
to prescribe these drugs for every ache and pain. At 
this tillie the indications for the use of these drugs 
are well established both by clinical investieation and 
experience as \Nell as by experimental work, anO. the medi-
cal profession contributes most to prophylaxis of severe 
toxic effects upon the blood by not using the drug 
ill-advisedly. 
If agranulocytosis has occurred during or 
bunediately following the ingestion of the sulfanilamide 
group of drugs, the drue must be discontinued at once 
if not already done. Elimination from the body is 
aided by forcing fluids. (68)(95) 
Anemia is usually not associated with 
agranulocytosis. Blood transfusions shonld be made if 
anemia is part of the picture. rrhe transfusions' how-
ever, do not stimulate the bone ~La:c-row and the relc:_tively 
few leukocytes added to the circulation are of little or 
no help for they are rapidly used. X-Ray over the long 
bones has been suggested to depress the bone marrow but 
this has been abandoned as well as the theory that if 
sepsis or necrosis is inducec1 the_:: need :Cor leukocytes 
will sti1aulate their production or maturation.(27) (L1.r:3) (44) 
Doan (23) says that nucleic acid exerts a 
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chemotactic ef:::'ect upon nornal nyeloicl foci and 
causes a pror.1r)t effective ir1crease in the deli very of 
leu....~ocytes to the peri}Jhe1~a1 vascular systea. Ee does 
not believe that spont&neous recovery occurs from 
agranulocytosis because he thinks it is due to an 
intrinsic deficiency phenomenon. The nucleic acid and 
nucleotides supply the :3timulus of maturation and the 
stinmluc-J of initiation of developnent 01' cells to mature 
leukocytes if the bone marroY1 is in a co~1di t ion to res-
pond. (80)(81) If the condition has proeressed to such 
a stage that the marrow has becofile aplastic, it will be 
ir.irossible for it to be stimulated by any i1roducts of 
nucleic acid. IIall \35) sue;gests yell011 bone marrow 
extract, because it supposedly supplies the intrinsic 
factor vJhich is able to cause the bone narrow to produce 
ni::..ture cells and. d.elive::: them to blood.. Yellmv bone 
marrow extr::::ct is given orally in capsules containing 
3.5 grains. :Fifty to one hundred capsules are given 
daily until monocytes appear in the blood, and monocytes' 
reappearance in the blood stream are said to be of 
favorable prognostic significance. If adenine sulfate 
is used it is surge sted that 1 grarl' be given intra-
muscularly three times a day until an incrs:-,,se in 
neutrophils begins. Jackson (43) advises pentnucleatide, 
10 cc. intravenously four tiBes a day. Ile has had very 
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good results vvith this substance. 
l'ron the cases reviewed, the best routine 
followed in treating agranulocytosis is to exclude the 
drug inmiediately and hasten its rapid excretion. 
Blood transfusion is necessary if the hemoglobin is 
less than 60?~. Since it is not known what type of 
mechanism is responsible for the dyscrasia, it seems 
that no harm is done by using some form of a nucleatide 
or liver extract. The diet should be cor:iplete and the 
patient given good nursing care. 
iiyperleukocytosis. 
Before leaving the discussion of white blood 
cell disturbances, a few reports of hyperleukocytosis 
have been made. Fitzhugh (27) and Alpert (2) have found 
this condition to occur es·pecially associated v'ii th drug 
fever and rash. A similar reaction has been noticed 
in laboratory animals.(64) 
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1. A review· of' the literature concerning the 
disturbances of the erythrocytes and leukocytes of the 
blood associated v1ith the aQ.7ninistration of para-amino-
benzene sulfonamide and its derivatives has been made. 
2. Both a chronic slowly-developir:..g hemolytic 
anemia and an acute hemolytic anemia are occasio11ally 
associated vlith the administration of these drues. 
3. Agranulocytosis and leucopenia are also 
associated with the ingestion of these drugs. 
4. These hematological dyscrasias are very 
similar to the sensitivity reactions caused by amino-
pyrine and other drugs of the amino benzene group of 
drugs. 
5. Possible etiological factors which may be 
concerned in the development of these types of drug 
idiosyncrasy are size of the dose of the drug, the 
length of' time the drug is e;iven, the sex: of the 
patient, the effect of the infectious process which is 
beine; tested, nnd the cumulative effect of the drug. 
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6. The actual mechanism of the production of 
the anemia is not known, nor is the aechanism. of the 
production of agranulocytosis understood. 
l.!_ There is no typical characteristic bone 
marrow picture associated vd th these conditions. 
~ The promiscuous use of the drugs of the 
para-amino-benzene sulf onarnide group is to be discour-
aged. This applies to the medical profession as well 
as to the laymen. 
9. 1fuenever the drug has been prescribed for 
a patient, the patient should be closely observed 
during the course of the drug therapy. If the 
response is not favorable, the drug should not be 
continued ove:::· too long a period of ti111e. 
* * * * * * 
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BIBLIOGRAPHY 
1. Allen, J. G.; Short, C.L. 
Granulocytopenia Associated with Sulfanilamide 
Therapy. 
New Eng.J.Hed. 219:6-8, July 1938 
2. Alpert, G.R.; Forbes, R.P. 
Granulocytopenia and Hyperleukocytosis Following 
Sulf anila.~ide Therapy 
J. Pediatrics 12:605-609, May 1938 
·3. Antopol, William; Robinson, Harry 
Pathologic and Histologic Changes Following Oral 
Administration of Sulfapyridine 
Arch.Path. 29:67-76, 1940 
4. Antopol, W.; Applebaum, Goldman L. 
Acute Hemolytic .Anemia 7Jith Autoagglutination 
Following Sulfanilamide Therapy 
J" .A.~,I.A. 113:488-489, Aug.1939 
5. Barnett, H.L.; Hartmann, A.F.; Perley, A .TI.; 
Ruhoff, Mary B. 
The Treatment of Pneumococcic Infections in 
Infants and Children with Sulfapyridine 
J.A.M.A. 112:518-527, 1939 
6. Berg, Samuel; Holtzman, Michael 
Fatal Granulocytopenia Following Sulfanilamide 
Therapy 
J .A.M.A. 110: 370-371, Jan. 1938 
7. Bigler, J.A.; Clifton, W.M.; ~erner, M. 
The Leukocyte Response to Sulfanilamide Therapy 
J .A.!1.,!.A. 110 :343-349, Jan. 1938 
8. Borst, J.G.G. 
Death from Agranulocytosis After Treatment with 
Prontosil Flavum 
Lancet 1:1519-1520, 1937 
9. Bresgen, c • 
. Zur Aetiologie der Agranulocytose 
Klin.1/fchnschr. 17:273-2'75, Feb. 1938 
i 
10. Britton, C.J.C.; Howkins, J. 
Action of Sulfanilamide on Leukocytes. 
Lancet, II + 718-720, Sept. 1938 
11. Buttle, G.A.H.; Stephenson, D.; Smith, S; 
Deuring, T.; Foster, G.C. 
'freatment of Streptococcal Infections in Eice 
with 4:4' Diaminodiphenylsulphone. 
Lancet, 1:1331-1334, June 1937 
12. Campbell, c.M. 
Effect of i~ulfanilamide on the Blood Picture .• 
Lancet 1:247-248, Jan. 1938 
13. Colebrook, L.; Kenny, M. 
rrreat:ment of Hur_mn Puerperal Infections in ~.~ice 
with Prontosil 
Lancet I;l2?0-1286, 1936 
14. Corr, P.; Root, R.N. 
Death from Granulocytopenia after Sulfanilamide 
Therapy 
J .A.11.A. 112: 1939-1940, :.~ay 1939 
15. Cbxon, R.V.; Forbes, J.R. 
Agranulocytic Angina Following Administration 
of M and B 693 (Sulfapyridine) 
Lancet 2:1412-1413, Dec. 1938 
16. Culbreath, Paul; Ellenton, s.c. 
Fatal Case of Agranulocytosis ~allowing Therapy 
J.South Carolina M.A •. 34:307-309, Dec. 1939 
17. Cutler, I.L.; Crane, E.J. 
Agranulocytosis Caused by Sulfanilamide 
Recovered Case 
New :;:!;ng.J.Med. 221:231-233, Aug.1939 
18. Danziger, L. 
Delayed Toxic Reaction of Sulfanilamide 
Bull. Johns Hopkins Hosp. 63:340-344, Nov. 1938 
19. Domagk, Gerhard 
Ein Beitrag zur Chemotherapie der Bakteriellen 
Infection 
Deutsche Med.Wchnschr. 61:250, Feb. 1935 
ii 
20. Domagk, G. 
Chemotherapie der Streptokokken Inf ektionem 
Klin.Wchnschr. 15:1585-1590, Get. 1937 
21. Domagk, G. 
Der derzeitige Stand der Chemotherapie der 
ba~teriellen Infectionem 
Ztschr. f. klin. :.:ed. 136:167-199, 1939 
22. Darling, R.C.; Parker, F.Jr.; Jackson, E. Jr. 
The Pathological Changes in Eone Earrow in 
Agranulocytosis. 
Am.J.Path. 12:1-12, 1936 
23. Doan, C.A. 
The Neutropenic State: Its ':'ignificance and 
Therapeutic Hationale 
J.A.~.A. 99:194-202, 1932 
24. Dolgopol, V.B.; Hobart, H.g. 
Granulocytopenia (and Leukopenia) in Sulfa-
pyridine Therapy 
J.A.~.A. 113:1012-1017, Sept.1939 
25. Evans, G.~.; Gainsford, Wilfrid F. 
rrrea tme~t of 1-'neu..monia vJi th 2- ( p-aminobenzene-
sulphona.~ido) pyridine 
Lancet II:l4-19, July 1938 
26. Finkelstone-Sayliss, E.; Paine, C.G.; 
_·'Jtrick, L.B. 
Bacteriostatic ~ction of p-amino Benzene 
Sulfonamide upon Hemolytic Streptococcus 
Lancet II: 792-796, Oct.1937 
27. Fitz-Hugh, T. Jr. 
f:'ens i ti vi ty He actions of Blood and Bone ?.:arrow 
to Certain Drugs 
J.A.Ll.A, 111:1643-1647, 1938 
28. Fitz-Hu0h, T.Jr.; Krumbhaar, ~~.B. 
:.Iyeloid Cell Eyper:plasia of the Done rCarrmv 
in Agranulocytic ~ngina 
_~,m.J.~~.sc. 183:104-110, 1932 
29. :Flippin, H.F.; Loclcwood, J.s.; Pepper, D.S.; 
Schwartz, Leon 
The Treatment of :?neumococcic J)newnonia with 
Sulfapyridine 
J.~.hl.A. 112:529, 1939 
iii 
30. Garvin, C.F. 
Corr1plications :?ollmving .~:dministration of 
()ulfanilamide 
J .A. ~.A. 113:288-291, July 1939 
31. Cray, H.C.; Adams, B. 
Treatment of Pnew.nococcic = eningi tis with Sulfa-
nilarn.ide and ;::;pecific 'erum.. :..:ase with 
.Agranulocytosis and Recovery. 
Einnesota ~edicine 22:369-373, June 1939 
32. Hageman, P.O. 
Clinical '.-;xperience in the Use of c~·Ulfanilamide 
at the New Haven Hospital 
Jour.Pediat. 11:195, August 1937 
33. Hageman, P.O. 
Toxicity of ~ulfanilamide. Study of Pathological 
Lesions in ... hi te :.:ice 
Proc.Soc.Exper.Biol. and '~d. 37:119-122, Oct.1937 
34. Hage:oan, ? • 0. ; Blake, ·.:rranci s, G. 
Clinical .l.Gxperience with ~·ulfanilamide in the 
Treatm.ent of beta-Hemolytic Streptococcus 
Infections 
Am.Jour.of I:ed.Sc. 195:163-175, l'eb. 1938 
35. Hall, B.:::. 
Influence of Sulfanilamide on Blood 
Pree.Staff ?.eat.of ::ayo Clinic 14:155-157, 1939 
36 • Hawking, 1''. 
Phar:c,:acologic L:.ctions of Sulphanila:::1ide 
Lancet II:l019-1021, Oct. 1937 
37. Eiggins, G.l':l.; T~achella, T.E. 
~-memia Induced by :ulfanilarJ.ide in the Presence 
of Nicotinic Acid 
Proo.Staff ~:eet. L:ayo Clin. 14:692-694, Nov. 1939 
38. I::arvey, ;, • I.:. ; Janeway, C. ,'J... 
The Development of Acute Hemolytic Anemia 
J.A.M.A. 109:12-15, July 1937 
39. Hodes, E.L.; Stifler, ·il.C.; ''alker, Ethel; 
;,:cc.:.~rty, i-aclyn; Shirley, I~.G. 
The Use of Sulfapyridine in I'rir'.'c<:1ry Pneuraococcic 
Pnew.nonia 
J.Pediat. 14:417-446, 1932 
iv 
40. Hoffman, B.J. 
Post-sulfanilaJ.nide Agranulocytosis Case with 
Recovery 
J.M.A. Georgia 28:166+167, April 1939 
41. Hohmann, 'ii. J. 
Control of Sulphanilamide Th~rapy 
Brit. E.J. 1:923,1938 
42. Ives, R.F. 
:Hemolytic Streptococcic .Angina with 
Agranulocytosis. Treated with Prontosil 
and Sulfanilamide. 
Ann.Int.Med. 102:882-88?, 1938 
43. Jackson, H. Jr.; Parker, F. Jr. 
Agranulocytosis: Its Etiology and Treatment 
New Eng.J.Bed. 220:729-732, 1935 
44. Jackson, Henry Jr.; Tighe, Thomas, J.G. 
An Analysis of the Treatment and Mortality 
of Three Hundred and Ninety Cases of Acute 
Agranulocytic Angina 
New Eng. J. Med. 212:137-148, 1935 
45. Jackson, H. Jr. 
The Differential Diagnosis of Agranulocytic 
Angina from Acute Leukemia 
.Arfl.J.l':.sc. 188:604-608, 1934 
46. Jennings, G.E.; Southwell-Sander, G • 
.Anemia and Agranulocytosis During Sulphanilamide 
Therapy 
Lancet II:898-902, 193? 
47. Johannsen, M.W.; St.George, A.V. 
48. 
49. 
Toxicity and Therapeutic Effects of Sulfapyridine 
in Animals 
.Arn.J.Clin.Path. 9:414-420, 1939 
Johnston, F.D. 
Granulocytopenia Following Administration of 
Sulphanilarn.ide Compounds. 
Lancet 2:1044-1047, Nov. 1938 
Jones, H.;·:.; Miller, C.P. 
Neu"(.ropenia Following Sulfanilamide 
J.Lab and Clin.:ied. 24:121-124, Nov.1938 
v 
50. Keefer, c.s. 
Sulfanila:rrdde: Its ?.~ode of Act ion and Use in 
the Treetment of Various Infections 
New Eng.J.~ed. 219:562-571, 1938 
51. Kohn, s.E. 
Acute Hemolytic .Anemia during Treatment with 
Sulfanilamide 
J.A.M.A. 109:1005, 1937 
52. Koletsky, s. 
Fatal Hemolytic Anemia following Adrainistration 
of Sulfanilamide 
J.A.~.A. 113:291-294, July 1939 
53. Kracke, R.R. 
J.\ Review of Granulocytopenia 
J.Lab.and Clin.IEed. 17:933-1005, 1932 
54. Kracke, R.R. 
The Experimental Production of Agranulocytosis 
Am.Jour.Clin.Path. 2:11-30, 1932. 
55. Kracke, R.R.; Parker, F.P. 
The Etiology of Granulopenia (Agranulocytosis) 
with Farticuler Reference to Drugs Containing 
the Benzene Ring. 
J .Lab. and Clin .I.iied. 19: 799-818, 1934 
56. Kracke, R.R. 
Helation of Drug Therapy to Neutropenic States 
J .A.L: •. A. 111:1255-1259, Oct.1938 
57. Kreutzman, Vl.B.; Corr, J.L. 
The Zff ect of Prontosil on Blood Cells 
Proc.Soc.Exper.Biol.and Med. 38:19-21, Feb. 1938 
58. Lloyd, V.:ii:.; Erskine, D. and Johnson, A.G. 
Chemotherapy of Gonorrhea with M & B 693 
Lancet II:ll60-1164, Nov. 1938 
59. Long, P.H.; Bliss, E.A. 
Toxic !~anifestations 
Ann.Surg. 108:808-812, Nov. 1938 
60 L P ,~ Bl. H' A. • ong, .rt.; iss, ~ •• 
Tbe Clinical Use of Sulfanilamide and Its 
Derivatives in the Trec:~tment of Infectious 
Diseases. 
Annals of Int.r:ed. 11:575-591, Nov.1937 
vi 
61. Long, P.H.; Bliss, E.A.; Feinstone, ~.H. 
tiode of Action, Clinical Use and Toxic 
i.1anifeststions of Sulfanila.mide 
J .A.:: . .A. 112:115-121, Jan. 1939 
62. Long, P.H.; Bliss, Eleanor 
Clinical Use of Sulfanilamide and Sulfapyridine 
and Allied Compounds 
MacT'"Iillan Company, New York, 1939 
63. Long, P.H.; Bliss, E.A.; Feinstone, W.H. 
Effects of Sulfapyridine, Sulfanilamide, and 
Related Compounds in Bacterial Infections 
Penn.Eed.Jour. 42:483-491, Feb. 1939 
64. Loseke, L. 
Constitutional Changes L:l Rabbi ts Subjected to 
Combined and Uncombined Fever and Sulfanilamide 
Therapy 
Thesis: Presented to Graduate Faculty, University 
of Nebraska, College of :Medicine, 1921-0. 
65. Machella, T.E.; Higgins, G.u. 
Anemia Induced in Rats b: the Administration of 
Sulfanilamide 
Proo.Staff .Meet.Mayo Clin. 14:183-185, March 1939 
66. Madison, F.W.; Squier, T.l .. 
The Etiology of Primary Granulocytopenia 
(Agranulocytic Angina} 
J.A.P.A. 102:755-759, 1934 
67. Marcus, N.L. 
Agranulocytosis and Sulfanilamide 
J.Florida M.A. 25:489-496, April 1939 
68. Marshall, E.K.Jr.; Kendall E. Jr.; Cutting, w.c. 
The Renal Excretion of Sulfanilamide 
J.Pharm.e.nd Exper.Therapeutics 61:191-195, Oct.1937 
69. Marshall, E.K.Jr.; Cutting, w·.c.; Kendall, .C.:merson 
The Toxicity of Sulfanilamide 
J.A.M.A. 110:252-257, Jan.1938 
70. McGuire, P.R.; McGuire, J.P. 
Agranulocytosis Following Use of Sulfanilamide 
Ill.M.J. 73:425-426, !,:Tay 1938 
vii 
71. !,Iodel, A. 
Agranulocytosis and Para-amino-benzene-sulfonamide 
Bri~.~.J. 11:295, 1937. 
72. Nl:olitor, Hans; Robinson, H. 
Acute, Cumulative and Chronic Toxicity of 
Sulfapyridine 
J.Pharm.& Exper.Therap. 65:405-423, April 1939. 
73. Nelson, A.A. 
Histopathologic Changes in Hens and Rabbits 
Following Administration of Sulfanilamide and 
Sulf anilyl Sulf anilamide 
Pub.Health Reports. 
74. Nelson, J!:.L.; Scott-Young, M. 
Profound Anemia Following Administration of 
Sulfanilamide in Acute Gonorrhea 
Med.Jour.Australia 1:626+627, April 1938 
75. Pearson, H.E.S. 
Fatal Agranulocytosis after Sulfonilamide 
Treatment 
Brit.~~ •. J. I:l031-1032, May 1939 
76. Pepper, O.H.R. 
Leukopenia: A Review with Special Reference 
to Agranulocytic Angina 
Calif. and Western Med. 35:173-177, 1931 
35:82-86, 1931 
77. Plumer, H.E. 
Prontylin and Frontosil 
New ~ng.Jour.of Med. 216:711, 1937 
78. Posner, I.; Guthrie, N.''1.; Ivlattice, H.R. 
ForJ:Ja tion of Abnormal Blood F'ignent as a Compli-
cation of SulfanilBlnide Therapy. 
J.Lab. and Olin.Med. 23:804-809, May 1938 
79. Ravinia, A. 
Indications et Accidents du Para-a.i-nino-phenyl-
sulfaJ:nide 
Presse Eed. 46: 332-336, ~.Iarch, 1938 
80. Reznikoff, P. 
Nucleotide Therapy in Agranulocytosis 
J.Clin.Investig. 9:381-391, 1930. 
viii 
81. Richmond, ~.L. 
Granulocytopenia F'ollowing Surgical Sepsis and 
Treated with Adenine Sulfate 
New Eng.J.Med. 221:26?-269, .Aug.1939 
82. Rimington, C. 
Porphyrinuria Following Sulf onilamide 
Dermatitis. 
Lancet 1:770-?76, April 1938 
83. Rosenblum, P.; Rosenbaum, .A.H. 
Severe Hemolytic Anemia Due to Sulfanilamide 
Arch.Pediat. 55:511-512, Aug. 1938 
84. Rosenthal, N.; Vogel,P. 
Granulocytopenia Caused by Gulfapyridine 
J .A.M.A. 113: 584-58?, Aug. 1939. 
85. Rosenthal, N. 
Hematological Aspects of Agranulocytosis and 
Other Diseases Accompanied by DXtreme Leukopenia 
iul1.J.Clin.Path. 1:7-31, 1931 
86. Rosenthal, S.M. 
Effects of Repeated Administration of Sulfa-
nilanide and Sulfanilyl Sulfanilamide to Rabbits 
and Chickens 
Pub.Health Heports 54:95-106, Jan. 1939 
87. Rosenthal, S .:r:.r.; Bauer, Hugo 
Colorimetric Tests for Aromatic Hydroxylamines 
and for Further Oxidation Products of Aromatic 
Amines. Their Demonstration in the Urine 
Following Sulfanilamide Administration 
Pub.Health Reports 54:1880-1890, Oct. 1939 
88. Sailor, Seaton 
Subacute Bacterial Endocarditis Treated with 
Sulfanilamide Resulting in Granulocytopenia 
and Death 
Am.J.Clin.Path. 9:269-279, 1939 
89. Schilling, V. The 
The Blood Picture, Translation by R.Graiwohl 
C.V.Mosby, St.Louis, 1929 
90. Schultz, W. 
Ueber eigenartige HalserkrarJ{ungen 
Deutsche med.Wchnschr. 48:1495-1496, 1922 
ix 
91. Schwartz, ·walter F.; Garvin, C.F.; Koletsky, Simon 
Fatal Granulocytopenia from Sulfani.iamicle 
J.A.M.A. 110:368-370, Jan. 1938 
92. Schwentker, F. F. 
Use of Sulfanilamide in Treatment of Infections 
M.Clin.N.A. 21:1449-1460, Sept. 1937 
93. Shecket, H.A.; Price, A.E • 
. Fatal Granulocytopenia J:iollowing Adrn.inistration 
of Sulfanilamide 
J.A.M.A. 112:823-828 
94. Shullenberger, l'T.A. 
Agranulocytosis following Treatment of Bacterial 
Infections with Sulfa.pyridine 
J.Indiana M.A. 32:415-417, Aug. 1939 
95. Stewart, J.D.; Rourke, G.U.; Allen, J.G. 
"Excretion of Sulfanilamide 
J.A.M.A. 110:1885-1887, 1938 
96. Strasser, A.; Singer, K. 
Ueber Prontosil-Hemoglobinurie und Andere 
Sulfanilamid-Blutschaedigungen 
Med.Klin. 34:783-784, June 1938 
97. Sutherland, M.E • 
. Agranulocytosis followin? Administration of 
M & B 693 (Sulfapyridine1 
Lancet !:1208-1209, May 1939 
98. Sweeney, Shirley J.; Allday, L.E. 
Granulocytopenia from Sulfanila.cuide ·lili th Unusual 
Blood Crisis and Recovery 
Ann.Int.Med. 13:1241-1243, 1940 
99. Taub, J.; Lefkowitz, L. 
Agronulocytosis Due to Sulfanilamide 
N.Y.State J.Med. 39:1659-1661, Sept. 1939 
100. Trefouel, J.; Trefouel, J. L~e.; Nitti, F.; 
Bouet, D 
Activite du p-amino phenylsulfamide sur les 
Infections Streptococcique Experimentales de 
la Souris et du Lapin 
Comp.rend.Soc.de Biol. 120:756, 1935 
x 
101. Trw.11per, A. 
Prontylin and Prontosil 
New Eng.Med.J. 216:857, 1937 
102. Van Duyn, J. 
Leukocyte ::I:xhaustion FollowL1g Surgical Procedure 
Arch.Surg. 37:302-310, 1938 
103. Whitby, L.E.H. 
Discussion on Use of Sulfanilamide and Allied 
Drugs in Treatment of Human and Animal Diseases. 
Proo.Roy.Soc.Med. 32:349-358, Feb. 1939 
104. 'Hien, R. 
Toxicity of (p-aminobenzenesulphonamido) Pyridine. 
Q.uant.J.Pharm. and Pharmacol. 11:217-224, 1938 
105. Willis, Thayer 
Sulfanilamide in Ophthalmia Neonatorum 
Yale Jour.Biol.and Med. 10:275, Jan. 1938 
106. Wood, W.B.Jr. 
Anemia During Therapy 
~.A.M.A. 111:1916-1919, Nov. 1938 
10?. ·wood, H. 
Fatality from Acute Hemolytic Anemia which 
Developed During Administration.of Sulfanilamide 
South.L:ed.Jour. 31:646-648, June 1938 
108. Young, C.J. 
Agranulocytosis and Para-amino-benzine-
Sulphonamide 
Brit.r~ecl.J. 1:105-106, 1937 
xi 
